02 Mar 2022 Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints
24 Feb 2022 Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an Adjuvanted Plant-Based COVID-19 Vaccine
23 Feb 2022 Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
23 Feb 2022 Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
21 Feb 2022 GSK provides update on phase III RSV maternal vaccine candidate programme
16 Feb 2022 European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults
16 Feb 2022 PharmaJet Partner Technovalia Announces Interim Results of Needle-free COVID-19 Vaccine Trial
16 Feb 2022 AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
12 Feb 2022 Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern
08 Feb 2022 Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
08 Feb 2022 Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
04 Feb 2022 Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
04 Feb 2022 AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
03 Feb 2022 EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea
02 Feb 2022 Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
01 Feb 2022 Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
01 Feb 2022 Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
01 Feb 2022 Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
28 Jan 2022 IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
27 Jan 2022 Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
25 Jan 2022 Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
25 Jan 2022 Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
13 Jan 2022 Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 Jan 2022 Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
07 Jan 2022 Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up